{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T17:00:31Z","timestamp":1770829231428,"version":"3.50.1"},"reference-count":26,"publisher":"The Endocrine Society","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2003,3,1]]},"abstract":"<jats:p>Cyclical iv therapy with pamidronate improves the clinical course in children and adolescents with osteogenesis imperfecta (OI). In this study we evaluated the effect of this therapy on bone and mineral metabolism in 165 patients with OI types I, III, and IV (age, 2 wk to 17.9 yr; 86 girls and 79 boys). All patients received iv pamidronate infusions on 3 successive days, administered at age-dependent intervals of 2\u20134 months. During the 3 d of the first infusion cycle, serum concentrations of ionized calcium dropped by 0.14 \u00b1 0.008 mmol (mean \u00b1 se; P &amp;lt; 0.001), and serum PTH levels transiently almost doubled (P &amp;lt; 0.001). At the same time, urinary excretion of the bone resorption marker type I collagen N-telopeptide related to creatinine (uNTX\/uCr) decreased by 61\u201373% (P &amp;lt; 0.001). Two to 4 months later, ionized calcium had returned to pretreatment levels, and uNTX\/uCr remained 30\u201335% lower than at baseline (P &amp;lt; 0.001). During 4 yr of pamidronate therapy (n = 40 patients), ionized calcium levels remained stable, but PTH levels increased by about 30% (P &amp;lt; 0.01). uNTX\/uCr, expressed as a percentage of the age- and sex-specific mean value in healthy children, decreased from 132 \u00b1 13% (mean \u00b1 se) at baseline to 49 \u00b1 3% after 4 yr of therapy (P &amp;lt; 0.001). In conclusion, serum calcium levels can decrease considerably during and after pamidronate infusions, requiring close monitoring especially at the first infusion cycle. In long-term therapy, bone turnover is suppressed to levels lower than those in healthy children. The consequences of chronically low bone turnover in children with OI are unknown at present.<\/jats:p>","DOI":"10.1210\/jc.2002-021371","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T02:02:44Z","timestamp":1047348164000},"page":"986-992","source":"Crossref","is-referenced-by-count":114,"title":["Osteogenesis Imperfecta Types I, III, and IV: Effect of Pamidronate Therapy on Bone and Mineral Metabolism"],"prefix":"10.1210","volume":"88","author":[{"given":"Frank","family":"Rauch","sequence":"first","affiliation":[{"name":"Genetics Unit, Shriners Hospital for Children and McGill University, Montre\u0301al, Que\u0301bec, Canada H3G 1A6"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Horacio","family":"Plotkin","sequence":"additional","affiliation":[{"name":"Genetics Unit, Shriners Hospital for Children and McGill University, Montre\u0301al, Que\u0301bec, Canada H3G 1A6"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rose","family":"Travers","sequence":"additional","affiliation":[{"name":"Genetics Unit, Shriners Hospital for Children and McGill University, Montre\u0301al, Que\u0301bec, Canada H3G 1A6"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonid","family":"Zeitlin","sequence":"additional","affiliation":[{"name":"Genetics Unit, Shriners Hospital for Children and McGill University, Montre\u0301al, Que\u0301bec, Canada H3G 1A6"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francis H.","family":"Glorieux","sequence":"additional","affiliation":[{"name":"Genetics Unit, Shriners Hospital for Children and McGill University, Montre\u0301al, Que\u0301bec, Canada H3G 1A6"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"80","reference":[{"key":"2020071617255978900_R1","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1136\/jmg.16.2.101","article-title":"Genetic heterogeneity in osteogenesis imperfecta.","volume":"16","author":"Sillence","year":"1979","journal-title":"J Med Genet"},{"key":"2020071617255978900_R2","first-page":"386","article-title":"Osteogenesis imperfecta","author":"Whyte","year":"1999","journal-title":"In: Favus MJ, ed. Primer on the metabolic bone diseases and disorders of mineral metabolism, 4th Ed. Philadelphia: Lippincott-Williams and Wilkins;"},{"key":"2020071617255978900_R3","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S8756-3282(00)00269-6","article-title":"Static and dynamic bone histomorphometry in children with osteogenesis imperfecta.","volume":"26","author":"Rauch","year":"2000","journal-title":"Bone"},{"key":"2020071617255978900_R4","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1002\/jbmr.5650090706","article-title":"Bone resorption assessed by immunoassay of urinary cross-linked collagen peptides in patients with osteogenesis imperfecta.","volume":"9","author":"Brenner","year":"1994","journal-title":"J Bone Miner Res"},{"key":"2020071617255978900_R5","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0022-3476(05)81038-8","article-title":"Hypercalciuria in children severely affected with osteogenesis imperfecta.","volume":"119","author":"Chines","year":"1991","journal-title":"J Pediatr"},{"key":"2020071617255978900_R6","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/8756-3282(94)00046-8","article-title":"Hypercalciuria in osteogenesis imperfecta: a follow-up study to assess renal effects.","volume":"16","author":"Chines","year":"1995","journal-title":"Bone"},{"key":"2020071617255978900_R7","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJM199810013391402","article-title":"Cyclic administration of pamidronate in children with severe osteogenesis imperfecta.","volume":"339","author":"Glorieux","year":"1998","journal-title":"N Engl J Med"},{"key":"2020071617255978900_R8","first-page":"1846","article-title":"Pamidronate treatment of severe osteogenesis imperfecta in children under 3 years of age.","volume":"85","author":"Plotkin","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071617255978900_R9","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1136\/adc.86.5.356","article-title":"Beneficial effect of long term intravenous bisphosphonate treatment of osteogenesis imperfecta.","volume":"86","author":"Astrom","year":"2002","journal-title":"Arch Dis Child"},{"key":"2020071617255978900_R10","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1359\/jbmr.2000.15.9.1650","article-title":"Type V osteogenesis imperfecta: a new form of brittle bone disease.","volume":"15","author":"Glorieux","year":"2000","journal-title":"J Bone Miner Res"},{"key":"2020071617255978900_R11","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1359\/jbmr.2002.17.1.30","article-title":"Osteogenesis imperfecta type VI: a form of brittle bone disease with a mineralization defect.","volume":"17","author":"Glorieux","year":"2002","journal-title":"J Bone Miner Res"},{"key":"2020071617255978900_R12","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S8756-3282(02)00790-1","article-title":"Osteogenesis imperfecta type VII: an autosomal recessive form of brittle bone disease.","volume":"31","author":"Ward","year":"2002","journal-title":"Bone"},{"key":"2020071617255978900_R13","first-page":"E680","article-title":"Influence of serum Ca concentration on circulating molecular forms of PTH in three species","volume":"251","author":"D\u2019Amour","year":"1986","journal-title":"Am J Physiol"},{"key":"2020071617255978900_R14","first-page":"613","article-title":"Fundamentals of clinical chemistry","author":"Tietz","year":"1976","journal-title":"Toronto: Saunders;"},{"key":"2020071617255978900_R15","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/S0022-3476(97)70162-8","article-title":"Urinary phosphate\/creatinine, calcium\/creatinine, and magnesium\/creatinine ratios in a healthy pediatric population.","volume":"131","author":"Matos","year":"1997","journal-title":"J Pediatr"},{"key":"2020071617255978900_R16","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1542\/peds.110.1.105","article-title":"Urinary excretion of cross-linked N-telopeptides of type 1 collagen to assess bone resorption in infants from birth to 1 year of age.","volume":"110","author":"Lapillonne","year":"2002","journal-title":"Pediatrics"},{"key":"2020071617255978900_R17","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/8756-3282(94)90888-5","article-title":"Bone resorption rates in children monitored by the urinary assay of collagen type I cross-linked peptides.","volume":"15","author":"Bollen","year":"1994","journal-title":"Bone"},{"key":"2020071617255978900_R18","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1093\/ajcn\/37.3.478","article-title":"Measurement of muscle mass in humans: validity of the 24-hour urinary creatinine method.","volume":"37","author":"Heymsfield","year":"1983","journal-title":"Am J Clin Nutr"},{"key":"2020071617255978900_R19","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S8756-3282(96)00224-4","article-title":"Clinical, biochemical, hematologic, and radiographic responses in Paget\u2019s disease following intravenous pamidronate disodium: a 2-year study.","volume":"19","author":"Gutteridge","year":"1996","journal-title":"Bone"},{"key":"2020071617255978900_R20","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1002\/jbmr.5650110817","article-title":"Comparison of biochemical markers of bone turnover in Paget disease treated with pamidronate and a proposed model for the relationships between measurements of the different forms of pyridinoline cross-links.","volume":"11","author":"Randall","year":"1996","journal-title":"J Bone Miner Res"},{"key":"2020071617255978900_R21","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1172\/JCI119668","article-title":"Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis.","volume":"100","author":"Chavassieux","year":"1997","journal-title":"J Clin Invest"},{"key":"2020071617255978900_R22","first-page":"333","article-title":"Molecular basis and clinical application of biological markers of bone turnover.","volume":"17","author":"Calvo","year":"1996","journal-title":"Endocr Rev"},{"key":"2020071617255978900_R23","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/0378-5122(96)01118-8","article-title":"Cyclical pamidronate infusions in postmenopausal osteoporosis.","volume":"25","author":"Peretz","year":"1996","journal-title":"Maturitas"},{"key":"2020071617255978900_R24","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1172\/JCI0215952","article-title":"The effects of intravenous pamidronate on the bone tissue of children and adolescents with osteogenesis imperfecta.","volume":"110","author":"Rauch","year":"2002","journal-title":"J Clin Invest"},{"key":"2020071617255978900_R25","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1210\/edrv.19.1.0325","article-title":"Bisphosphonates: mechanisms of action.","volume":"19","author":"Fleisch","year":"1998","journal-title":"Endocr Rev"},{"key":"2020071617255978900_R26","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1359\/jbmr.1997.12.1.6","article-title":"Bone microdamage and skeletal fragility in osteoporotic and stress fractures.","volume":"12","author":"Burr","year":"1997","journal-title":"J Bone Miner Res"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/88\/3\/986\/9148656\/jcem0986.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/88\/3\/986\/9148656\/jcem0986.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,17]],"date-time":"2020-07-17T03:29:18Z","timestamp":1594956558000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/88\/3\/986\/2845107"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,3,1]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2003,3,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jc.2002-021371","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,3,1]]}}}